Torrent Pharmaceuticals Executive Director Amal Kelshikar resigns
Torrent Pharmaceuticals has announced the resignation of Amal Kelshikar, its Executive Director, effective 16 October 2026. Kelshikar, who joined the company in May 2022, cited a desire to transition as the reason for his departure. His resignation was filed under SEBI Listing Regulations.
Editor, Lazyfounder
30 SEC SUMMARY
- Amal Kelshikar has resigned as Executive Director of Torrent Pharmaceuticals, effective 16 October 2026.
- Kelshikar cited a desire to transition as the reason for his departure after nearly three decades in the pharmaceutical and healthcare industries.
- His resignation was filed under SEBI Listing Regulations, formalizing the leadership change.
- Kelshikar previously held leadership roles at Novartis, Baxter Healthcare, AstraZeneca, and Abbott.
- He joined Torrent Pharmaceuticals as Executive Director in May 2022.
TABLE OF CONTENTS
KEY HIGHLIGHTS
- Amal Kelshikar resigned as Executive Director of Torrent Pharmaceuticals, with his departure taking effect on 16 October 2026.
- He stated his reason for leaving as a desire to transition, according to his resignation letter.
- Kelshikar’s resignation was submitted under Regulation 30 of the SEBI Listing Regulations.
- He has nearly 30 years of experience in the pharmaceutical and healthcare sectors, including roles at Novartis, Baxter Healthcare, AstraZeneca, and Abbott.
- Kelshikar joined Torrent Pharmaceuticals as Executive Director in May 2022.
Why Kelshikar resigned
According to Mint, Amal Kelshikar resigned from his position as Executive Director of Torrent Pharmaceuticals, citing a desire to transition as the reason for his departure. His resignation will take effect on 16 October 2026. The company has formally accepted his decision, which was filed under Regulation 30 of the SEBI Listing Regulations.
Kelshikar’s career before Torrent Pharmaceuticals
Amal Kelshikar brings nearly three decades of experience in the pharmaceutical and healthcare industries. He began his career at Novartis India, where he served as Head of Strategic Planning and Business Development. He later took on regional roles, including Head of Mature Products BU/BDL for Asia Pacific at Novartis Singapore and Commercial Director at Novartis Philippines.
After Novartis, Kelshikar joined Baxter Healthcare as General Manager. He then moved to AstraZeneca Philippines, where he served as President. In May 2012, he joined Abbott, holding multiple leadership positions, including Managing Director and General Manager for the India region, General Manager for Singapore, and Divisional Vice President for Asia Pacific.
Before joining Torrent Pharmaceuticals, Kelshikar had a brief stint as a business management consultant and was associated with the NUS Graduate Research Innovation Programme.
Education and professional development
Kelshikar holds an undergraduate degree in chemical engineering from the University Department of Chemical Technology in Mumbai. He also completed an MBA (PGDM) in marketing, finance, and strategy from the Indian Institute of Management (IIM) Ahmedabad. Additionally, he undertook an Executive Marketing Program at Kellogg Executive Education.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
Amal Kelshikar’s resignation from Torrent Pharmaceuticals marks the end of a chapter for the company, but it also reflects a broader trend in the pharmaceutical industry: seasoned executives often transition to new opportunities after decades of leadership. For founders and operators, Kelshikar’s career offers a case study in how regional and global roles can build deep industry expertise. His move also serves as a reminder of the importance of compliance in leadership changes, particularly for companies subject to regulatory frameworks like SEBI’s. While Torrent Pharmaceuticals will need to navigate this transition, Kelshikar’s departure could open doors for new leadership to steer the company in a fresh direction.
Key takeaways
- Torrent Pharmaceuticals will undergo a leadership transition with Kelshikar’s departure, which could impact its strategic direction or operational priorities in the near term.
- Founders and executives in the pharmaceutical sector may note Kelshikar’s career trajectory as an example of how regional and global leadership roles can shape long-term executive growth.
- The formal resignation process under SEBI Listing Regulations highlights the importance of compliance in corporate governance, especially for publicly listed companies.
- Kelshikar’s diverse experience across multiple multinational companies underscores the value of cross-functional and cross-geographical roles in building executive expertise.
FAQ
What was Amal Kelshikar’s role at Torrent Pharmaceuticals?
Amal Kelshikar served as Executive Director of Torrent Pharmaceuticals until his resignation, effective 16 October 2026.
Why did Amal Kelshikar resign from Torrent Pharmaceuticals?
Kelshikar cited a desire to transition as the reason for his resignation in his letter to the company.
What companies did Amal Kelshikar work for before joining Torrent Pharmaceuticals?
Before joining Torrent Pharmaceuticals, Kelshikar held leadership roles at Novartis, Baxter Healthcare, AstraZeneca, and Abbott.
What regulatory process did Kelshikar’s resignation follow?
His resignation was filed under Regulation 30 of the SEBI Listing Regulations, which governs disclosure requirements for listed companies in India.
Related on Lazyfounder
Sources
- Mint (Technology) · 2026-10-18
Who is Amal Kelshikar? Why did he resign from the position of Torrent Pharmaceuticals' Executive Director? Explained
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.
